- Conditions
- Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
- Interventions
- CUE-102
- Drug
- Lead sponsor
- Cue Biopharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 17,835
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Olmsted Syndrome
- Interventions
- KM-023, Placebo
- Drug
- Lead sponsor
- Orvida Pharma (formerly Kamari Pharma)
- Network
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Niraparib 200 mg, Cetrelimab 240 mg, Cetrelimab 480 mg, Abiraterone acetate 1000 mg, Prednisone 5 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Denver, Colorado • Jacksonville, Florida + 15 more
- Conditions
- Congenital Heart Disease
- Interventions
- Entresto Pill, Placebo
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Solid Tumors
- Interventions
- nesvacumab (REGN910/ SAR307746), aflibercept (ziv-aflibercept)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • New York, New York • Oklahoma City, Oklahoma + 2 more
- Conditions
- Emphysema, Alpha 1-Antitrypsin Deficiency
- Interventions
- Hyaluronic Acid Inhalation Solution, Placebo Inhalation Solution
- Drug
- Lead sponsor
- Gerard Turino
- Individual
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 5
- States / cities
- Miami, Florida • Fayetteville, New York • Charleston, South Carolina + 2 more
- Conditions
- IBS
- Interventions
- VSL#3
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- MEDI7510, IIV
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 363 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Orlando, Florida • South Miami, Florida • Kansas City, Missouri + 2 more
- Conditions
- Atrial Fibrillation
- Interventions
- Omega -3 fatty acids, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetic Chronic Kidney Disease
- Interventions
- GCS-100, Placebo
- Drug
- Lead sponsor
- La Jolla Pharmaceutical Company
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 8
- States / cities
- Chula Vista, California • El Centro, California • La Jolla, California + 5 more
- Conditions
- Lung Cancer (Diagnosis)
- Interventions
- Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block
- Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- lenalidomide, melphalan, prednisone
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Interventions
- paclitaxel, cisplatin, topotecan hydrochloride, filgrastim
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Respiratory Illness
- Interventions
- Low Dose CT scan
- Diagnostic Test
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Total Knee Arthroplasty
- Interventions
- Hydrocortisone, Placebo
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- Acidform 5 g, Placebo 4 g, Acidform 4 g, Acidform 3 g
- Drug
- Lead sponsor
- Evofem Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Cleveland, Ohio
- Conditions
- Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
- Interventions
- Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 20
- States / cities
- La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
- Conditions
- Hematological Malignancies
- Interventions
- Full intensity, double umbilical cord, stem cell transplant, Flu/Bu4 conditioning regimen, Total Lymphoid Irradiation (TLI), Graft versus Host Disease prevention (GVHD prophylaxis), Mycophenolate Mofetil
- Procedure · Drug · Radiation
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate
- Interventions
- LI, Cyclophosphamide, Indomethacin, Zinc, Surgery, Cisplatin, Radiotherapy
- Biological · Drug · Dietary Supplement + 2 more
- Lead sponsor
- CEL-SCI Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 928 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 5
- States / cities
- Springfield, Illinois • Detroit, Michigan • Cincinnati, Ohio + 2 more
- Conditions
- Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
- Interventions
- Placebo, Lumacaftor Plus Ivacaftor Combination, Ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 46
- States / cities
- Oakland, California • Sacramento, California • Aurora, Colorado + 43 more
- Conditions
- ADHD
- Interventions
- OROS-Methylphenidate (MPH)
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 7 Years to 11 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Seattle, Washington
- Conditions
- Recurrent Glioblastoma
- Interventions
- Intensity Modulated Proton Therapy (IMPT), Bevacizumab
- Radiation · Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Cirrhosis
- Interventions
- OCR-002 IR Oral Tablet, OCR-002 Oral Solution, OCR-002 IV Solution
- Drug
- Lead sponsor
- Ocera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Coronado, California
- Conditions
- Influenza, Healthy
- Interventions
- Trivalent Influenza Vaccine, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 3
- States / cities
- Miami, Florida • Stockbridge, Georgia • Portland, Oregon